Pandorum, a biotechnology company working in the space of Tissue Engineering and Regenerative Medicine with RnD labs and clinical centers in India and the US. At Pandorum, we have developed a technology platform to develop exosomes with tunable cargos from clinical grade Mesenchymal Stem Cells (with existing Drug Master File at USFDA) in a scalable and consistent manner. Using specific inducers, we can optimize the properties of these exosomes, such as, anti-inflammatory, anti-fibrotic, anti-angiogenic, neurogenesis to fit the need of a specific tissue and disease indication, such as cornea, liver and beyond. Our flagship product Kuragenx - the 'Liquid' Cornea, combines exosomes containing specialized cargos delivered with cornea-mimetic biopolymers to promote corneal tissue regeneration. Kuragenx can be visualized as a transparent viscous liquid that is administered dropwise to the excavated wound site after the corneal surgeon removes the diseased tissue. The liquid spreads, solidifies within a few minutes under visible light and helps to grow a new cornea in less than a year. Kuragenx was developed using quantitative experimental data including in vitro and in vivo studies to ‘map’ various tissue-states in order to assess the effectiveness of the treatment. Studies in New Zealand rabbits suffering from Neurotrophic Keratitis have demonstrated restoration of healthy cornea with neuronal plexus within three months post-treatment, paving the way to treat patients suffering from unmet clinical needs. Kuragenx has been assigned by USFDA to the Office of Tissues and Advanced Therapies, and our First in Human clinical study is planned in 2024, to treat advanced keratitis- a severe indication with unmet medical needs.